Document Classification

Section Type: RESULTS

Text: Consistent with the underlying hepatitis, relative to non-co-infected patients the co-infected patients, had a higher incidence of hepatic AEs [co-infected : 13 (18 %) etravirine-treated versus 10 (15 %) placebo-treated patients ; non-co-infected : 36 (7 %) versus 32 (6 %), respectively], and grade 3/4 elevation of AST [co-infected : 8 (11 %) versus 5 (7 %), respectively ; non-co-infected : 14 (3 %) versus 9 (2 %), respectively] and ALT [co-infected : 10 (14 %) versus 6 (9 %), respectively ; non-co-infected : 14 (3 %) versus 8 (2 %), respectively].